Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Email Promoting Instruments for Compelling Efforts - 2Prehistoric wolf’s gut frozen in time reveals an ice age giant
- 3Longtime United Launch Alliance CEO Tory Bruno resigns from space company. 'Finished the mission I came to do.'
- 4Which sandwich do you find totally delectable? !
- 5Former biotech CEO sued over COVID vaccine alleged insider trading
- Are Iraqi militias crossing into Iran to support Iran's war effort?
- Bomb blast in packed Nigerian mosque kills five
- Figure out How to Pick a SUV with Senior-Accommodating Tech Elements
- NASA loses contact with its Maven spacecraft orbiting Mars for the past decade
- How will the universe end?
- JW Marriott Tokyo: an elegant retreat amid whirlwind of the city
- The most effective method to Pick the Right Old Consideration Administration: Key Contemplations
- How Trump's marijuana executive order could change medical research landscape
- Nigeria warns its citizens in South Africa to be cautious after march turns violent
